IDEAS home Printed from https://ideas.repec.org/p/ohe/briefg/002084.html
   My bibliography  Save this paper

Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward

Author

Listed:
  • Neri, M.
  • Towse, A.
  • Garau, M.

Abstract

Multi-indication pricing (MIP) is based on the idea of recognising the value of all the indications, or patient sub-groups, for which a product is authorised. In principle, the implementation of MIP could achieve improvements in both static and dynamic efficiency - prices can be set at a cost-effective level for each indication and patient sub-population, thereby expanding treatment to more patients and stimulating future research as manufacturers anticipate a sufficient return on R&D spending. Despite its theoretical attractiveness, MIP is perceived as entailing a number of challenges and complications over the more widely used single pricing across indications. These include concerns around the appropriation of consumer surplus by manufacturers, leading to higher budget impact as the patient population grows in size, as well as complexity and inadequateness of the health system capabilities required to implement MIP. This report provides a detailed summary of a panel discussion held at the HTAi 2017 annual meeting in Rome on the current approaches to MIP in Europe, the perceived challenges, and how they could be tackled in the future. Erratum - 06/02/2019 - Please note that this copy of the report (originally published 28/11/2018) has been updated to correct an error in Section 3.

Suggested Citation

  • Neri, M. & Towse, A. & Garau, M., 2018. "Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward," Briefings 002084, Office of Health Economics.
  • Handle: RePEc:ohe:briefg:002084
    as

    Download full text from publisher

    File URL: https://www.ohe.org/system/files/private/publications/MIP%20briefing%20clean_CORRECTED.pdf
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Berdud, M. & Garau, M. & Neri, M. & O'Neill, P. & Sampson, C. & Towse, A., 2018. "R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C," Research Papers 002040, Office of Health Economics.
    2. Patricia Danzon & Adrian Towse & Jorge Mestre‐Ferrandiz, 2015. "Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context," Health Economics, John Wiley & Sons, Ltd., vol. 24(3), pages 294-301, March.
    3. Cole, A. & Towse, A. & Lorgelly, P. & Sullivan, R., 2018. "Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals," Research Papers 002030, Office of Health Economics.
    4. Mestre-Ferrandiz, J. & Towse, A. & Dellamano, R. & Pistollato, M., 2015. "Multi-indication Pricing: Pros, Cons and Applicability to the UK," Seminar Briefings 001653, Office of Health Economics.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Carlos Campillo-Artero & Jaume Puig-Junoy & José Luis Segú-Tolsa & Marta Trapero-Bertran, 2020. "Price Models for Multi-indication Drugs: A Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 18(1), pages 47-56, February.
    2. Rosella Levaggi & Paolo Pertile, 2020. "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition," Applied Health Economics and Health Policy, Springer, vol. 18(3), pages 357-362, June.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jorge Mestre-Ferrandiz & Néboa Zozaya & Bleric Alcalá & Álvaro Hidalgo-Vega, 2018. "Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?," PharmacoEconomics, Springer, vol. 36(12), pages 1407-1420, December.
    2. Berdud, M. & Chalkidou, K. & Dean, E. & Ferraro, J. & Garrison, L. & Nemzoff, C. & Towse, A., 2019. "The Future of Global Health Procurement: Issues around Pricing Transparency," Research Papers 002150, Office of Health Economics.
    3. Levaggi, Rosella, 2014. "Pricing schemes for new drugs: A welfare analysis," Social Science & Medicine, Elsevier, vol. 102(C), pages 69-73.
    4. Chen, Xu & Yang, Huan & Wang, Xiaojun, 2019. "Effects of price cap regulation on the pharmaceutical supply chain," Journal of Business Research, Elsevier, vol. 97(C), pages 281-290.
    5. Suzanne Hill & Leslie Olson, 2014. "NICE, Social Values, and Balancing Objectivity and Equity," PharmacoEconomics, Springer, vol. 32(11), pages 1039-1041, November.
    6. Jobjörnsson, Sebastian & Forster, Martin & Pertile, Paolo & Burman, Carl-Fredrik, 2016. "Late-stage pharmaceutical R&D and pricing policies under two-stage regulation," Journal of Health Economics, Elsevier, vol. 50(C), pages 298-311.
    7. R. Rovbel L. & Р. Ровбель Л., 2018. "Анализ проблем и возможностей использования референтного ценообразования органами государственной власти и местного самоуправления в сфере закупок и жилищного строительства // Analyzing the Problems a," Управленческие науки // Management Science, ФГОБУВО Финансовый университет при Правительстве Российской Федерации // Financial University under The Government of Russian Federation, vol. 8(2), pages 44-51.
    8. Carlos Campillo-Artero & Jaume Puig-Junoy & José Luis Segú-Tolsa & Marta Trapero-Bertran, 2020. "Price Models for Multi-indication Drugs: A Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 18(1), pages 47-56, February.
    9. Michael Drummond & Adrian Towse, 2019. "Is rate of return pricing a useful approach when value-based pricing is not appropriate?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(7), pages 945-948, September.
    10. Roediger, Alexander & Wilsdon, Tim & Haderi, Artes & Pendleton, Kathy & Azais, Boris, 2019. "Competition between on-patent medicines in Europe," Health Policy, Elsevier, vol. 123(7), pages 652-660.
    11. Mahlich Jörg & Sindern Jörn & Suppliet Moritz, 2015. "Vergleichbarkeit internationaler Arzneimittelpreise," Perspektiven der Wirtschaftspolitik, De Gruyter, vol. 16(2), pages 164-172, June.
    12. Gregory S. Zaric, 2016. "Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine," PharmacoEconomics, Springer, vol. 34(7), pages 635-644, July.
    13. Culyer, Anthony J., 2016. "Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use," Health Economics, Policy and Law, Cambridge University Press, vol. 11(4), pages 415-432, October.
    14. Rosella Levaggi & Paolo Pertile, 2021. "A reply to “Who would benefit from average value‐based pricing?”," Health Economics, John Wiley & Sons, Ltd., vol. 30(9), pages 2284-2286, September.
    15. Dominik J. Wettstein & Stefan Boes, 2019. "Effectiveness of National Pricing Policies for Patent-Protected Pharmaceuticals in the OECD: A Systematic Literature Review," Applied Health Economics and Health Policy, Springer, vol. 17(2), pages 143-162, April.
    16. Towse, A. & Cole, A. & Zamora, B., 2018. "The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries," Consulting Reports 002009, Office of Health Economics.
    17. Doug Coyle & Isabelle Durand-Zaleski & Jasmine Farrington & Louis Garrison & Johann-Matthias Graf von der Schulenburg & Wolfgang Greiner & Louise Longworth & Aurélie Meunier & Anne-Sophie Moutié & Ste, 2020. "HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(9), pages 1421-1437, December.
    18. Berdud, M. & Garau, M. & Neri, M. & O'Neill, P. & Sampson, C. & Towse, A., 2018. "R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C," Research Papers 002040, Office of Health Economics.
    19. Stéphane Alcenat & François Maréchal & Florence Naegelen, 2021. "Implementation of personalized medicine in a context of moral hazard and uncertainty about treatment efficacy," International Journal of Health Economics and Management, Springer, vol. 21(1), pages 81-97, March.

    More about this item

    Keywords

    Economics of Innovation; Value; Affordability; and Decision Making;
    All these keywords.

    JEL classification:

    • I1 - Health, Education, and Welfare - - Health

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ohe:briefg:002084. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: . General contact details of provider: https://edirc.repec.org/data/ohecouk.html .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Publications Manager (email available below). General contact details of provider: https://edirc.repec.org/data/ohecouk.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.